Short bowel syndrome (SBS) is a rare and potentially life-threatening malabsorptive condition resulting from loss of significant mass of functional bowel or physical bowel. There are many reasons for loss of bowel mass, including congenital defects, disease (e.g. Crohn’s disease) and intestinal resection. Short bowel syndrome can affect both adults and children. People with SBS may also develop chronic Type III intestinal failure (SBS-IF), and require long-term parenteral support (PS), consisting of parenteral nutrition and/or intravenous fluids. Issues related to PS include catheter-related bloodstream infections, venous thrombosis, metabolic bone disease, liver damage and psychosocial and financial problems. Treatments for SBS-IF have
generally focused on optimising dietary interventions, and antisecretory and
antidiarrhoea medication, with surgery an option for a small number of patients. More recently, emphasis has been on promotion of intestinal rehabilitation and
improvement of absorption, including the use of the recombinant analogue of
glucagon-like peptide 2 (GLP-2).
Original languageEnglish
PublisherEvidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence
Number of pages142
Publication statusPublished - 20 Sept 2017

Bibliographical note

Scotland G, Kopasker D, Scott N, Cruickshank M, Hernández R, Fraser C, McLean M, McKinlay A, Brazzelli M. Teduglutide for treating short bowel syndrome. Aberdeen HTA Group, 2017

This report was commissioned by the NIHR HTA Programme as project number 15/07/04

The authors are grateful to Lara Kemp for her administrative support.
Copyright is retained by Shire for Tables 1, 3, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28 , 29, 39, 31, 32, and 33, and for Figures 1, 2, 5, 6 , 7, 9, 10, 11, and 12


Dive into the research topics of 'Teduglutide for treating short bowel syndrome'. Together they form a unique fingerprint.

Cite this